자가면역질환 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global autoimmune disease therapeutics market size is expected to reach USD 231.15 Billion in 2034 from USD 168.72 Billion in 2025, growing at a CAGR of 3.56% during 2026-2034.This market is expanding as healthcare systems increasingly recognize the burden of autoimmune disorders and invest in improved diagnosis and treatment options. Growing prevalence of conditions affecting the immune system is supporting demand for targeted therapies and advanced treatment approaches. Pharmaceutical companies are developing biologics, immunomodulators, small-molecule therapies, and other precision treatment options. Increasing healthcare expenditure and improved access to specialist care are also supporting treatment adoption. Greater disease awareness among patients and healthcare professionals is encouraging earlier diagnosis and longer-term disease management.

Technological advances in drug discovery are creating new opportunities for therapeutic development. Researchers are increasingly focusing on biological pathways and molecular targets associated with immune dysfunction, enabling more targeted approaches. Improvements in diagnostic testing can help identify disease characteristics and support treatment selection. Pharmaceutical companies are also exploring combination therapies and personalized treatment strategies to address differences in patient response. Expanding clinical research and investment in novel therapeutic platforms are expected to strengthen the pipeline for autoimmune disease treatments.

Future prospects are closely linked to continued innovation, clinical success, regulatory approvals, and patient access. Increasing development of targeted and personalized therapies could improve treatment options for patients with complex autoimmune conditions. Biosimilars may also influence treatment accessibility and healthcare costs as established biologic therapies face greater competition. Companies are expected to invest in next-generation immunotherapies, biomarkers, and precision medicine approaches. As research improves understanding of autoimmune mechanisms, the therapeutic landscape is likely to become more diversified and increasingly focused on individualized disease management.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Systemic
• Organ-specific

By Drug Type

• Immunosuppressants
• Anti-Inflammatory Drugs
• Corticosteroids
• Nonsteroidal anti-inflammatory drugs
• Others

COMPANIES PROFILED

• AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Roche Holding AG, Sanofi, Bristol Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., UCB S.A., Biogen Inc., Boehringer Ingelheim, Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Galapagos NV

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Systemic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Organ-specific Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Type
• 5.2. Immunosuppressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Anti-Inflammatory Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Nonsteroidal anti-inflammatory drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Disease Type
  • 6.2.2 By Drug Type
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Disease Type
  • 6.3.2 By Drug Type
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Disease Type
  • 6.4.2 By Drug Type
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Disease Type
  • 6.5.2 By Drug Type
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Disease Type
  • 6.6.2 By Drug Type
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Amgen Inc
  • 8.2.3 Johnson & Johnson
  • 8.2.4 Novartis AG
  • 8.2.5 Roche Holding AG
  • 8.2.6 Sanofi
  • 8.2.7 Bristol Myers Squibb Company
  • 8.2.8 Eli Lilly And Company
  • 8.2.9 Pfizer Inc
  • 8.2.10 AstraZeneca PLC
  • 8.2.11 Merck & Co.Inc
  • 8.2.12 UCB S.A
  • 8.2.13 Biogen Inc
  • 8.2.14 Boehringer Ingelheim
  • 8.2.15 Takeda Pharmaceutical Company Limited
  • 8.2.16 Janssen Pharmaceuticals
  • 8.2.17 Gilead SciencesInc
  • 8.2.18 Teva Pharmaceutical Industries Ltd
  • 8.2.19 Viatris Inc
  • 8.2.20 Galapagos NV